IMX101

**IMX101** is an investigational therapeutic vaccine developed by ImevaX for *Helicobacter pylori* infection. The multicomponent vaccine contains *H. pylori* gamma-glutamyl transpeptidase and an undisclosed *H. pylori* outer-membrane protein antigen, together with a mucosal fusion-protein adjuvant. It is designed to generate neutralizing antibody responses against gamma-glutamyl transpeptidase, an immune-evasion factor, and cytotoxic T-cell responses against the outer-membrane antigen to support bacterial eradication. IMX101 completed a randomized, double-blind, adjuvant-controlled Phase 1a/b trial in *H. pylori*-negative and *H. pylori*-infected healthy volunteers. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/helicobacter-pylori-therapeutic-vaccine-imx101))

Other names

Helicobacter pylori therapeutic vaccine IMX101IMX101 vaccineIMX-101 vaccineIMX 101 vaccine